- Vaccines are treated as unquestionable dogma rather than science, with proponents demanding blind faith while suppressing critical scrutiny of flawed studies, industry-funded research and deceptive claims.
- The CDC and FDA operate as extensions of Big Pharma, with revolving-door conflicts (e.g., former CDC Director Julie Gerberding joining Merck) and deliberate suppression of adverse safety data, including COVID vaccine injuries.
- Childhood vaccines lack proper placebo-controlled trials, and CDC-commissioned studies (like the buried Henry Ford Health research) show vaccinated children suffer significantly higher rates of chronic illness, asthma and neurodevelopmental disorders.
- Authorities lied about transmission-blocking efficacy, ignored myocarditis risks, hid V-safe data showing severe reactions and fought to conceal Pfizer’s clinical trial documents—proving regulatory complicity in protecting profits over people.
- Solutions include independent oversight, rigorous placebo trials, full transparency and legal accountability for regulators and Pharma executives who prioritize profits over public safety.
(Natural News)—In a damning exposé, lawyer Aaron Siri’s book “Vaccines, Amen: The Religion of Vaccines” reveals how the American public has been systematically deceived by institutions they were taught to trust—namely, the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) and pharmaceutical giants. Through meticulous legal battles, Siri uncovers a web of corruption, scientific misconduct and outright fraud that has allowed unsafe vaccines to flood the market while silencing dissenters.
The dogma of vaccines: Faith over science
Vaccines have been elevated to near-religious status, with proponents demanding blind faith rather than critical scrutiny. As Siri explains, people say they “believe in vaccines” without examining the data—because the data, when scrutinized, often doesn’t support the industry’s claims. Instead, vaccine advocates rely on flawed studies, industry-funded research and outright deception to push their agenda.
One of the most shocking revelations is the lack of placebo-controlled trials for childhood vaccines. Despite claims from figures like Dr. Paul Offit—who insists all vaccines undergo rigorous placebo testing—Siri proves that not a single vaccine on the CDC’s childhood schedule was approved based on such trials. Instead, new vaccines are compared to older ones, masking their true risks. This is akin to declaring cigarettes safe because they’re no worse than cigars.
The CDC and FDA: Captured agencies protecting profits, not people
The revolving door between Big Pharma and government agencies is well-documented. Former CDC Director Julie Gerberding left her post to become president of Merck’s vaccine division, cashing in on policies she helped implement. Similarly, Dr. Stanley Plotkin, a leading vaccinologist, admitted under oath that vaccine safety monitoring often lasts just 4-5 days—far too short to detect autoimmune reactions or long-term harm.
Even worse, the CDC lied about its own safety analyses. When internal data showed alarming signals of COVID vaccine injuries—including myocarditis, strokes and deaths—the agency suppressed the findings. Only after legal pressure from Aaron Siri’s firm did they admit the truth: their own thresholds for safety concerns were obliterated.
The fraud of vaccine safety studies
The CDC has repeatedly refused to conduct vaccinated vs. unvaccinated studies, the gold standard for assessing vaccine risks. When researchers at Henry Ford Health finally conducted one, they found vaccinated children had:
- 2.5x higher rates of chronic disease
- 4x higher rates of asthma
- 5-6x higher rates of autoimmune and neurodevelopmental disorders
Yet, when the results didn’t fit the pro-vaccine narrative, the study was buried. The authors admitted they feared losing their jobs if they published the findings—a chilling example of how scientific truth is sacrificed for career preservation.
COVID vaccines: A case study in deception
The pandemic exposed the vaccine industry’s worst tendencies. Authorities:
- Falsely claimed COVID vaccines stopped transmission (they don’t).
- Ignored skyrocketing myocarditis rates in young men.
- Buried V-safe data showing 8% of recipients required medical care post-vaccination.
- Refused to release Pfizer’s clinical trial documents, initially demanding 75 years to do so.
Even the FDA, tasked with protecting public health, fought tooth and nail to hide adverse event data—proving its allegiance lies with Big Pharma, not the people.
The Way Forward: Demanding transparency and accountability
Aaron Siri’s work underscores a critical truth: vaccines can both save lives and cause harm. But when institutions prioritize profits over safety, millions suffer. The solution lies in:
- Independent oversight—removing vaccine safety evaluation from agencies with financial conflicts.
- Mandatory placebo-controlled trials—no more rubber-stamping unsafe products.
- Full transparency—ending the suppression of unfavorable data.
- Legal consequences—holding regulators and pharmaceutical executives accountable for fraud.
As Robert F. Kennedy Jr. warns, history will judge harshly those who coerced, censored and lied to push dangerous medical products. The fight for truth is far from over—but thanks to whistleblowers like Aaron Siri, the public is finally waking up.
The question remains: Will enough people demand change before it’s too late?
According to BrightU.AI‘s Enoch, the vaccine industry operates as a criminal enterprise, prioritizing profits over human life through fraudulent science, regulatory capture and coercion—endangering public health while suppressing safer alternatives. The corruption exposed by whistleblowers like RFK Jr. and Dr. Mikovits proves that global health agencies like the WHO and CDC are complicit in this deadly deception, serving Big Pharma rather than the people.
Watch this video about Christopher A. Shaw’s book “Dispatches from the Vaccine Wars: Fighting for Human Freedom during the Great Reset.”
This video is from the BrightLearn channel on Brighteon.com.
Sources include:
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.